Finished product reference
Ripasudil
Solution, Drops · Ophthalmic · 0.4 % · 5 mL
- List code
- 52944
- Pharmacologic class
- Antiglaucoma agent (Rho kinase inhibitor)
What it is and how it works
Ripasudil inhibits Rho-associated protein kinase (ROCK), relaxing the trabecular meshwork and Schlemm’s canal cells and increasing conventional aqueous humour outflow. This lowers intraocular pressure.
Indications
Glaucoma and ocular hypertension when other treatments are insufficiently effective or not appropriate.
Dosage and administration (summary)
One drop of the 0.4% ophthalmic solution in the affected eye(s) twice daily.
Contraindications
Hypersensitivity to ripasudil or any component of the eye drops.
Warnings and precautions
Conjunctival hyperaemia is very common, usually transient after instillation; blepharitis and allergic conjunctivitis may occur. Separate from other eye drops by at least 5 minutes, and contact lenses should be removed before instillation.
Storage and supply
Store at room temperature, protected from light; discard the bottle within the period stated by the manufacturer after opening.
Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.